The antibody contract manufacturing market
Roots Analysis has announced the
addition of the “Antibody Contract
Manufacturing Market, 2020-2030”
report to its list of offerings.
Although
biopharmaceuticals offer significant profit margins and have been proven to be
effective in treating a myriad of diseases, they are generally associated with
high costs of development and complex manufacturing protocols; this is true for
antibody-based products as
well. Presently, there are a number of companies that claim to offer end-to-end
solutions, ranging from antibody development to commercial production. Further,
prevalent trends suggest that sponsor companies are likely to continue relying
on contract service providers for various aspects of antibody-based product
development and manufacturing.
To order this 285+ page report, which features
100+ figures and 110+ tables, please visit https://www.rootsanalysis.com/reports/view_document/antibody-cmo-market/295.html
Key
Market Insights
Over
100 CMOs presently claim to offer manufacturing services for antibodies
The
antibody contract
manufacturing market is currently dominated by the presence of small and
mid-sized companies, which represent 70% of the industry stakeholders. It is
also worth highlighting that more than 55% of CMOs claim to have the
capabilities to manufacture antibodies across all scales of operation
(preclinical, clinical and commercial).
More than 90% service providers are focused on the
production of monoclonal antibodies
However,
players based in Asia are now increasingly focusing on the development of
bispecific antibodies for therapeutic use. It worth highlighting that close to
20% of the CMOs engaged in this domain claim to offer manufacturing services
for both bispecific antibodies and antibody fragments.
Europe has emerged as a key manufacturing hub for antibody-based
products
More
than 120 manufacturing facilities have been established by various players,
worldwide; of these, 40% are in Europe. Additionally, 40% of the total
installed capacity is in Europe, followed by Asia. Some of the prominent
regions in Asia include (in decreasing order of number of manufacturing
facilities) China, South Korea, India, Japan and Taiwan.
More
than 90 partnership agreements have been inked between 2013 and 2019
Majority
of these agreements were focused on manufacturing of various types of
antibodies. Other popular types of collaboration models include process
development and manufacturing agreements (22%), product development and
manufacturing agreements (10%) and licensing agreements (7%).
Multiple
expansion initiatives were undertaken by CMOs between 2017 and 2019
More
than 50% of such initiatives were reported to be focused on the expansion of
manufacturing facilities, followed by building new facilities (38%). It is
worth noting that close to 50% of the total number of expansion initiatives
were undertaken in Europe, of which, 25% were in the UK.
Demand
for therapeutic antibodies is anticipated to grow at a CAGR of 10%, during
2020-2025
Given
the fact that there are a number of antibody-based products in the market, the
commercial demand for antibodies is significantly higher than the clinical
demand. Across the three major global regions, North America represent over
half of the overall global manufacturing demand for antibodies.
North
America and Europe are anticipated to capture over 70% of the market share by
2030
However,
the market in the Asia is anticipated to grow at a relatively faster rate.
Further, presently, more than 90% of the antibodies are being developed using
mammalian expression systems, and this trend is unlikely to change
significantly in short to mid-term.
To request a sample copy / brochure of this
report, please visit https://www.rootsanalysis.com/reports/295/request-sample.html
Key Questions Answered
§
Who are the leading CMOs engaged in the production of
antibody-based therapeutics?
§
What kind of partnership models are commonly adopted by
stakeholders in this industry?
§
What is the annual clinical and commercial demand for
antibody-based products?
§
What is the current installed capacity for manufacturing of
antibodies?
§
What are the various expansion initiatives undertaken by
antibody CMOs?
§
How is the current and future market opportunity likely to
be distributed across key market segments?
The
USD 17 billion (by 2030) financial opportunity within the antibody contract
manufacturing market has been analyzed across the following segments:
§
Type of Antibodies
§
Monoclonal Antibodies
§
Bispecific Antibodies
§
ADCs
§
Others
§
Company Size
§
Small
§
Mid-sized
§
Large / Very Large
§
Scale of Operation
§
Preclinical / Clinical
§
Commercial
§
Type of expression
system used
§
Mammalian
§
Microbial
§
Key geographical
regions
§
North America
§
Europe
§
Asia and RoW
The
report features inputs from eminent industry stakeholders, according to whom
antibody therapeutics developers are increasingly outsourcing their
manufacturing operations owing to complex nature of the overall process, as
well as the high investments associated with setting-up in-house expertise. The
report includes detailed transcripts of discussions held with the following
experts:
§
Dietmar Katinger (Chief Executive Officer, Polymun
Scientific)
§
David C Cunningham (Director, Corporate Development,
Goodwin Biotechnology)
§
Claire Otjes (Marketing Manager, Batavia Biosciences)
The
research covers profiles of key players that offer manufacturing services for
antibodies, featuring a company overview, information on their respective
service portfolios, manufacturing facilities and capabilities, and an informed
future outlook.
§
AGC Biologics
§
Aldevron
§
AMRI
§
Boehringer Ingelheim BioXcellence
§
Emergent BioSolutions
§
Eurofins CDMO
§
FUJIFILM Diosynth Biotechnologies
§
KBI Biopharma
§
Lonza
§
Nitto Avecia Pharma Services
§
Novasep
§
Pierre Fabre
§
Samsung BioLogics
§
Synthon
§
Thermo Fisher Scientific
For
additional details, please visit
https://www.rootsanalysis.com/reports/view_document/antibody-cmo-market/295.html or
email sales@rootsanalysis.com
You
may also be interested in the following titles:
1.
Bispecific Antibody
Therapeutics Market (4th Edition), 2019-2030
2.
Antibody Drug
Conjugates (ADCs) - Linker and Conjugation Technologies Market, 2019-2030
3.
Antibody Drug
Conjugates Market (5th Edition), 2019-2030
About Roots Analysis
Roots Analysis is one of the fastest
growing market research companies, sharing fresh and independent perspectives
in the bio-pharmaceutical industry. The in-depth research, analysis and
insights are driven by an experienced leadership team which has gained many
years of significant experience in this sector. If you’d like help with your
growing business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots Analysis Private
Limited
Gaurav Chaudhary
+1 (415) 800 3415
Facebook - https://www.facebook.com/RootsAnalysis
LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
Twitter - https://twitter.com/RootsAnalysis
Medium - https://medium.com/@RootsAnalysis
Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/
Comments
Post a Comment